<DOC>
	<DOC>NCT02539849</DOC>
	<brief_summary>FOS improve gut colonization by Faecalibacterium prausnitzii in patients with Crohn's disease</brief_summary>
	<brief_title>Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With CrohnÂ´s Disease</brief_title>
	<detailed_description>To demonstrate that FOS increases counts of Faecalibacterium prausnitzii in faecal samples from Crohn's disease patients</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients between 18 and 65 years old Crohn's disease patients Inflammatory activity confirmed by imaging techniques (colonoscopy or magnetic resonance imaging (MRI)) Refractory inflammatory luminal disease (with or without perianal involvement) at any level of the gastrointestinal tract requiring therapy with adalimumab,according to standard clinical practice. Stable maintenance of any other medication (corticosteroids and / or immunosuppressants and/or 5aminosalicylic acid (5ASA)) for the past 4 weeks Screening tests required for a safe administration of anti tumour necrosis factor (antiTNF) antibodies will be performed according to standard clinical practice Subjects consuming prebiotic supplements (inulin, FOS, galactooligosaccharides (GOS)) in their regular diet. Antibiotic use within the past 2 months Previous antiTNF therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>